Altria's (MO) NJOY obtains authorization from the U.S. Food and Drug Administration for menthol e-vapor products.
Vous n'êtes pas connecté
Synaptogenix, Inc., an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, announced that the Food & Drug Administration (FDA) has authorized an Investigational New Drug
Altria's (MO) NJOY obtains authorization from the U.S. Food and Drug Administration for menthol e-vapor products.
TUESDAY, July 2, 2024 -- A new drug to treat Alzheimer's disease was approved by the U.S. Food and Drug Administration on Tuesday. In clinical trials,...
DAEJEON, South Korea, July 2, 2024. PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing...
STAMFORD, Conn., July 01, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused...
PLYMOUTH MEETING, Pa., June 24, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration...
RenovoRx, Inc, a clinical─stage biopharmaceutical company developing novel precision oncology therapies based on a local drug─delivery platform,...
Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the...
BASKING RIDGE, N.J. & RAHWAY, N.J., June 26, 2024 – The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL)...
Cartesian Therapeutics, Inc, a clinical─stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, announced that the first...
NORTH CHICAGO, Ill., June 25, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it received a Complete Response Letter (CRL) from the U.S. Food...